Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CuraGen has advanced CR011-vcMMAE, an antibody-drug conjugate, into Phase II for the treatment of patients with unresectable stage III and stage IV melanoma.
Subscribe to our email newsletter
CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics’s proprietary technology.
Ronit Simantov, vice president of medical development and chief medical officer of CuraGen, said: “We are pleased with the progress achieved in the CR011-vcMMAE clinical program. Advancing this program into Phase II is an important development milestone as we look to establish the role of CR011-vcMMAE in the treatment of patients with advanced melanoma.”